Lactobacillus reuteri DSM 17938

ApprovedBiologic

MMedical University of Warsaw

Lactobacillus reuteri DSM 17938 is one of 50 biologic programs targeting Cerebral Palsy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyActive, not recruiting

Necrotizing EnterocolitisActive, not recruiting

Cerebral PalsyApproved

Active, not recruiting

Necrotizing EnterocolitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Cerebral Palsy

#DrugCompanyPhaseTrials

Ingrezza

Neurocrine Biosciences

Phase 3

1 2

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 3

3 3

Advil

KKenvue Brands

Phase 3

1 4

Cyklokapron

AAmring

Phase 3

1 5

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 6

Dysport

Ipsen

Phase 3

1 7

Lactobacillus reuteri DSM 17938

MMedical University of Warsaw

Approved

1 8

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Phase 3

1 9

Fosamax

Mylan Pharmaceuticals Inc

Phase 3

1 10

PROCRIT

WWim Janssens

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diarrhea2 trials

Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children

Completed·EEskisehir Osmangazi University·Phase 4·NCT02765217·1,325 enrolled

Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial

Completed·MMedical University of Warsaw·Phase 4·NCT02871908·250 enrolled

Cerebral Palsy1 trial

Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation

Completed·AAndrea Garcia Contreras·Phase 4·NCT03117322·40 enrolled

Necrotizing Enterocolitis1 trial

The Role of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants

Unknown status·—·Phase 2·NCT04541771·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Lactobacillus reuteri DSM 17938. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactobacillus reuteri DSM 17938 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactobacillus reuteri DSM 17938. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Warsaw company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: MMedical University of Warsaw

Lactobacillus reuteri DSM 17938

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diarrhea2 trials

Cerebral Palsy1 trial

Necrotizing Enterocolitis1 trial

References

Drug Info

Quick Facts

Related News